ea0099ep592 | Reproductive and Developmental Endocrinology | ECE2024
Bar On Shelly
, Yaish Iris
, Barzilai Merav
, Greenman Yona
, Gindis Guy
, Moshe Yaffa
, Tordjman Karen
Background: Sublingual estradiol (E) for gender-affirming hormone therapy (GAHT) of transgender women (TW) might obviate the need for an anti-androgen, and mitigate pro-coagulant changes. We recently showed that 2 mg E, divided into 4 daily SL doses (SLE), offers no clinical advantage over the same dose given orally in combination with cyproterone acetate (CPA). Furthermore, we showed that after each sublingual administration, serum E2 (sE2) peaked to levels, the likes of whic...